Analysis of drug resistance to anti-tuberculosis drugs of 115 retreatment smear-positive pulmonary tuberculosis

doi:10.3969/j.issn.1000-6621.2018.03.015

Abstract

Abstract:

Objective To investigate the status of drug resistance of 115 retreatment smear-positive tuberculosis patients and to analyze the causes of drug resistance.Methods We collected 115 retreatment smear-positive tuberculosis patients from Shaanxi Tuberculosis Prevention and Treatment Institute and newly registered outpatients from Xijing Hospital, and did the Mycobacterium isolation and strain identification with their sputum specimens. After strain culture, 97 Mycobacterium were isolated, of which 93 has obtained drug susceptibility testing (referred to as “susceptibility testing”) results. Mycoplasma strains were identified as 2 non- and 91 Mycobacterium tuberculosis. We took these 91 tuberculosis patients as research object, and did the susceptibility testing with six kinds of anti-TB drugs (rifampicin (RFP), isoniazid (INH), streptomycin (Sm), ethambutol (EMB), levofloxacin (Lfx), Kanamycin (Km)). We analyzed the status of drug resistance and further investigated the causes of drug resistance formation.Results For the 91 retreatment smear-positive tuberculosis patients, the total drug resistance rate was 42.86% (39/91), single-drug resistant rate was 30.77% (28/91), multi-drug resistant rate was 6.59% (6/91), the multidrug-resistant rate (MDR) was 4.40% (4/91) and the extensively drug resistant rate (XDR) was 1.10% (1/91). Single-drug resistant rates from high to low were: Lfx (12.09%, 11/91), Sm (7.69%, 7/91), RFP (5.49%, 5/91), INH (2.20%, 2/91), EMB (2.20%, 2/91), Km (1.10%, 1/91). Drug resistance analysis found, that medical factors accounted for 57.14% (16/28), patient’s own factors accounted for 28.57% (8/28), and the drug factors accounted for 14.29% (4/28).Conclusion The total drug resistant rate is relatively high for the 115 retreatment smear-positive tuberculosis patients, and the non-standard anti-TB drug treatment is the main cause for drug resistance.

Key words: Tuberculosis,pulmonary, Retreatment, Tuberculosis,multidrug-resistant, Data interpretation,statistical, Factor analysis,statistical

Lin ZHANG,Jian KANG,Xiao-ping XIAN. Analysis of drug resistance to anti-tuberculosis drugs of 115 retreatment smear-positive pulmonary tuberculosis[J]. Chinese Journal of Antituberculosis, 2018, 40(3): 292-295. doi: 10.3969/j.issn.1000-6621.2018.03.015

Figures/Tables 2

References 10

[1]	袁磊凌, 李家政, 邹远华 , 等. 佛山市涂阳肺结核患者耐药情况分析. 结核病与肺部健康杂志, 2014,3(1):40-45. doi: 10.3969/j.issn.2095-3755.2014.01.009 URL
[2]	中国防痨协会基础专业委员会. 结核病诊断实验室检验规程.北京: 中国教育文化出版社, 2006: 46-65.
[3]	陈明亭, 李仁忠, 阮云洲 . 耐多药结核病防治标准化培训教程.北京: 人民卫生出版社, 2015: 1-2.
[4]	李仁忠, 阮云洲, 苏伟 , 等. 耐多药结核病防治标准化培训县(区)级教程.北京: 人民卫生出版社, 2015: 2.
[5]	中华人民共和国疾病预防控制局, 中华人民共和国卫生部医政司, 中国疾病预防控制中心. 中国结核病防治规划实施工作指南(2008年版). 北京: 人民卫生出版社, 2009: 55.
[6]	World Health. The stop TB strategy: building on and enhancing DOTS to treat the TB-related millennium deve-lopment goals. Geneva:World Health Organization, 2015.
[7]	全国第五次结核病流行病学抽样调查技术指导组, 全国第五次结核病流行病学抽样调查办公室. 2010年全国第五次结核病流行病学抽样调查报告. 中国防痨杂志, 2012,34(8):485-508.
[8]	张天华, 刘卫平, 李妍 , 等. 陕西省肺结核耐药性监测分析. 中国热带医学, 2017,3(2):113-115. doi: 10.13604/j.cnki.46-1064/r.2017.03.04 URL
[9]	黄静静, 熊昌富, 王春雷 , 等. 2013—2014年海南省初复治涂阳肺结核患者耐药监测结果分析. 中国防痨杂志, 2017,39(1):96-98. doi: 10.3969/j.issn.1000-6621.2017.01.021 URL
[10]	王玉红, 董雅坤, 王智慧 , 等. 首次复治涂阳肺结核患者耐药情况分析. 中国防痨杂志, 2017,39(2):180-183. doi: 10.3969/j.issn.1000-6621.2017.02.015 URL

因素	例数	构成比(%)
医原性因素
单一用药	2	7.14
联合用药不合理	10	35.71
药物剂量不足	3	10.71
疗程不足	1	3.57
合计	16	57.14
患者自身因素
依从性差	4	14.29
服药不正确	1	3.57
有其他基础疾病	3	10.71
合计	8	28.57
药物因素
药品质量无保证	3	10.71
其他原因导致药物供应间断	1	3.57
合计	4	14.29

[1]	Ge Qiping, Zhang Lijie, Huang Xuerui, Jiang Guanglu, Han Xiqin, Wang Jingping, Du Jian, Ma Yan, Gao Weiwei. Effect of a new treatment regimen on patients with initially retreated drug-sensitive pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(11): 1078-1083.
[2]	YANG Yang, YUAN Yuan, LU Shui-hua. Preliminary study on the clinical characteristics of 41 children with retreated drug-sensitive tuberculosis [J]. Chinese Journal of Antituberculosis, 2022, 44(1): 106-109.
[3]	ZHANG Li-jie*, HAN Xi-qin, WANG Jing-ping, CHEN Yu-hui, CHEN Sheng-yu, CHEN Ling, LI Bo, LIN Ming-gui, LI You-lun, SHI Lian, XI Xiu-e, MA Li-ping, WANG Xin, WANG Fei, ZHAO Cai-yan, WANG Fu-rong, CHEN Sen-lin, WU Xiang, LI Po, ZHANG Peng, LENG Xue-yan, ZHANG Hai-qing, CAO Wen-li, SHU Wei, SUN Yu-xian, XIE Shi-heng, TIAN Xi-zhong, HUANG Xue-rui, DU Jian, GAO Wei-wei. The relationship between bacterial load and treatment failure and recurrence of sputum positive retreatment pulmonary tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 335-340.
[4]	GE Qi-ping*, DU Jian, SHU Wei, MA Yan, MA Li-ping, ZHAO Cai-yan, CHEN Yu-hui, ZHANG Li-jie, HUANG Xue-rui, HAN Xi-qin, CHEN Sheng-yu, WANG Fei, LI Bo, CAO Wen-li, LIU Qian-ying, CHEN Dong-jin, SHI Lian, WANG Xin, LI You-lun, YANG Shang-peng, PENG Zhang-li, WU Chao, OUYANG Bing, WANG Fu-rong, LI Po, WU Xiang, XI Xiu-e, LENG Xue-yan, ZHANG Hai-qing, LI Hua, LI Juan, YANG Cheng-qing, ZHANG Peng, CUI Hong-zhe, XIE Li, LIU Yu-hong, LI Liang, GAO Wei-wei. Treatment effect analysis of the optimized regimen for re-treated drug-susceptible pulmonary tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 328-334.
[5]	SHU Wei, GE Qi-ping, HUANG Xue-rui, MA Li-ping, JI Bin-ying, CHEN Yu-hui, CHEN Xiao-you, JIANG Guang-lu, XIE Li, LI Bo, CHEN Sheng-yu, CHEN Sen-lin, YAN Jun-ping, SHI Lian, CHEN Ling, LI You-lun, XI Xiu-e, LIU Qian-ying, YAN Xing-lu, WANG Fei, WANG Fu-rong, WU Xiang, ZHANG Peng, LENG Xue-yan, CAO Wen-li, ZHANG Hai-qing, CUI Hong-zhe, YANG Cheng-qing, WU Chao, LI Juan, LI Hua, SUN Yu-xian, ZHANG Li-jie, XIE Shi-heng, NING Yu-jia, TIAN Xi-zhong, DU Jian, LI Liang, GAO Wei-wei. Analysis of treatment outcomes of retreated pulmonary tuberculosis patients with isoniazid-resistance and rifampin-resistance [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 322-327.
[6]	MA Yan*, GAO Wei-wei. Pay attention to the reasonable treatment of retreatment tuberculosis:today is not what it used to be [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 313-317.
[7]	Shanghai Clinical Research Center for Infectious Disease (Tuberculosis)/Shanghai Pulmonary Hospital, Tongji University School of Medicine, Beijing Chest Hospital , Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis . Expert consensus on the diagnosis and treatment of retreatment pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2021, 43(12): 1226-1238.
[8]	CHEN Shuang-shuang, SHA Wei, LIU Xiao-ning, MA Rong, CHENG Jie, LI Ye, WANG Xin-qiang, KAN Xiao-hong. Efficacy evaluation of short-course chemotherapy in patients with retreated pulmonary tuberculosis for the first time [J]. Chinese Journal of Antituberculosis, 2021, 43(11): 1153-1158.
[9]	LIU Zhi-bin, WU Min, WU Xiao-cui, HAN Min, ZHANG Qing, SHA Wei. Individualized treatment for retreatment smear-positive pulmonary tuberculosis patients based on molecular drug susceptibility testing and its short-term effectiveness [J]. Chinese Journal of Antituberculosis, 2021, 43(10): 1010-1015.
[10]	CHENG Wu, TAN Shou-yong, LI Yan, LI Qiong. Clinical characteristics of retreated bacterial negative pulmonary tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2021, 43(10): 1006-1009.
[11]	YING Ruo-yan, HUANG Xiao-chen, WANG Jie, LIU Yi-dian, SHA Wei, YANG Hua. Analysis of the correlation between sensitivity of drugs in the treatment and the outcome of treatment in pulmonary tuberculosis patients retreated for the first time [J]. Chinese Journal of Antituberculosis, 2021, 43(10): 1001-1005.
[12]	QIU Lei,ZHANG Shao-yan,GUO Xiao-yan,FU Ji-you,TIAN Li-ming,ZHANG Hui-yong,LU Zhen-hui. Clinical value of chemotherapy regimen and Qinbudan tablet on the retreatment of retreated smear-positive pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(2): 108-114.
[13]	YANG Jia,LYU Sheng-xiu,TANG Guang-xiao,SHU Wei-qiang,WANG Hui-qiu,YANG Chang-ping,LIU Xue-yan,LI Chun-hua. Analysis of CT findings in patients with initial and retreated multidrug-resistant tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(1): 38-43.
[14]	Jian DU,Xi-qin HAN,Wei SHU,Zi CHEN,Shi-heng XIE,Xiao-ya LYU,Qi-ping GE,Yan MA,Yu-hong LIU,Liang LI,Wei-wei GAO. Analysis of risk factors for recurrence of pulmonary tuberculosis after successful completion of treatment of relapsed smear positive tuberculosis [J]. Chinese Journal of Antituberculosis, 2019, 41(6): 624-631.
[15]	Bi-tong WU,Lan TAO,Yan-qiong LI,Guo-biao LIU,Jing ZHONG,Kun-hong JIANG,Li-qian HE,Shou-yong TAN. Analysis of curative effect of short-term chemotherapy regimen and standard chemotherapy regimen on first-time retreated multidrug-resistant pulmonary tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2018, 40(6): 639-643.